prednisolone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 153 Diseases   74 Trials   74 Trials   10107 News 


«12...1011121314151617181920...8586»
  • ||||||||||  prednisolone / Generic mfg., vinblastine / Generic mfg.
    Journal:  Langherhans cell histiocytosis presenting as primary infertility in a young male. (Pubmed Central) -  Oct 9, 2021   
    A final diagnosis of LCH involving pituitary and thyroid was made and patient was then started on treatment according to LCH treatment protocol LCH III-6 consisting of prednisolone and vinblastine (6 weeks with daily 40 mg/m2 oral prednisolone, and 6 mg/m2 i.v. vinblastine every 7 days). Patient is responding well to the therapy and is on follow up.
  • ||||||||||  hydroxychloroquine / Generic mfg.
    Clinical, Retrospective data, Journal:  Efficacy of hydroxychloroquine for treating annular erythema associated with Sjögren's syndrome. (Pubmed Central) -  Oct 7, 2021   
    Topical corticosteroids and tacrolimus, and oral corticosteroids, have been used as treatments for this condition...In the analysis of six patients who had taken oral prednisolone before starting HCQ, all were able to reduce the dose within 52 weeks without relapse...However, neither serious adverse events nor adverse events requiring discontinuation of treatment occurred. The results of the present study suggest that HCQ may not only be highly effective as a single agent, but may also be useful as a steroid-sparing agent in refractory case requiring long-term steroid administration, making it a good treatment option for AESS.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Clinical, Journal:  An update on adalimumab for pyoderma gangrenosum. (Pubmed Central) -  Oct 7, 2021   
    Adverse events were reported by 18 patients, most commonly infections (n = 11) and serious adverse events (n = 4). These results suggest that adalimumab is effective and generally well tolerated in Japanese patients with pyoderma gangrenosum active ulcers.
  • ||||||||||  Not your usual rash, DRESS syndrome () -  Oct 1, 2021 - Abstract #EUSEM2021EUSEM_3521;    
    The patient stopped taking the allopurinol after rash appearance and started taking Loratadine asper advise of her GP with no help...She has background of AF on warfarin, IHD, HTN and gout...started on oral prednisolone and admitted for about 2 weeks...The overall mortality in DRESS syndrome is about 10%.1 The most common differential diagnoses for DRESS syndrome are Stevens-Johnson syndrome/toxic epidermal necrolysis, hyper-eosinphillic syndrome and Kawasaki disease. Important learning points is to recognised the typical rash with associated sepsis-like syndrome and manage DRESS with immediately stopping the offending drug and use of steroids.
  • ||||||||||  Not your usual rash, DRESS syndrome () -  Oct 1, 2021 - Abstract #EUSEM2021EUSEM_3520;    
    The patient stopped taking the allopurinol after rash appearance and started taking Loratadine asper advise of her GP with no help...She has background of AF on warfarin, IHD, HTN and gout...started on oral prednisolone and admitted for about 2 weeks...The overall mortality in DRESS syndrome is about 10%.1 The most common differential diagnoses for DRESS syndrome are Stevens-Johnson syndrome/toxic epidermal necrolysis, hyper-eosinphillic syndrome and Kawasaki disease. Important learning points is to recognised the typical rash with associated sepsis-like syndrome and manage DRESS with immediately stopping the offending drug and use of steroids.
  • ||||||||||  Not your usual rash, DRESS syndrome () -  Oct 1, 2021 - Abstract #EUSEM2021EUSEM_3519;    
    The patient stopped taking the allopurinol after rash appearance and started taking Loratadine asper advise of her GP with no help...She has background of AF on warfarin, IHD, HTN and gout...started on oral prednisolone and admitted for about 2 weeks...The overall mortality in DRESS syndrome is about 10%.1 The most common differential diagnoses for DRESS syndrome are Stevens-Johnson syndrome/toxic epidermal necrolysis, hyper-eosinphillic syndrome and Kawasaki disease. Important learning points is to recognised the typical rash with associated sepsis-like syndrome and manage DRESS with immediately stopping the offending drug and use of steroids.
  • ||||||||||  Not your usual rash, DRESS syndrome () -  Oct 1, 2021 - Abstract #EUSEM2021EUSEM_3518;    
    The patient stopped taking the allopurinol after rash appearance and started taking Loratadine asper advise of her GP with no help...She has background of AF on warfarin, IHD, HTN and gout...started on oral prednisolone and admitted for about 2 weeks...The overall mortality in DRESS syndrome is about 10%.1 The most common differential diagnoses for DRESS syndrome are Stevens-Johnson syndrome/toxic epidermal necrolysis, hyper-eosinphillic syndrome and Kawasaki disease. Important learning points is to recognised the typical rash with associated sepsis-like syndrome and manage DRESS with immediately stopping the offending drug and use of steroids.
  • ||||||||||  prednisolone / Generic mfg.
    Biomarker, Journal:  Long-term outcomes and prognostic factors in generalized myasthenia gravis. (Pubmed Central) -  Sep 30, 2021   
    Approximately 60% of the MG patients achieved the treatment goal within 2 years after treatment. PSL dose and the cumulative number of plasmapheresis procedures at 3 months after immunotherapy initiation may help identify treatment-resistant patients with MG.
  • ||||||||||  Neulasta (pegfilgrastim) / Roche
    Trial completion, Enrollment change, Trial completion date:  Pegfilgrastim in Patients With Alcoholic Hepatitis (clinicaltrials.gov) -  Sep 29, 2021   
    P2,  N=34, Completed, 
    PSL dose and the cumulative number of plasmapheresis procedures at 3 months after immunotherapy initiation may help identify treatment-resistant patients with MG. Recruiting --> Completed | N=78 --> 34 | Trial completion date: Dec 2033 --> Mar 2021
  • ||||||||||  hydroxychloroquine / Generic mfg., cyclosporine / Generic mfg.
    [VIRTUAL] Toxic Epidermal Necrolysis (TEN) Associated with covid-19 Infection, a Case Report () -  Sep 25, 2021 - Abstract #AAPNCE2021AAP_NCE_1758;    
    He was treated with supportive care, IVIG 1 g/Kg daily for 5 days, IV dexamethasone shifted later to oral Prednisolone, Cyclosporin 3 mg/kg/day...There were case reports of TEN associated with Covid 19 infection in adults with probable association with drugs such as hydroxychloroquine (3), Allopurinol (5), Lamotrigine (6), one case with no history of drug exposure (7)...Both pediatrics cases had history of Amoxicillin- Clavulanate use... Whether Covid 19 infection can trigger TEN in pediatrics patient is an important question that needs larger studies, yet it is worth reporting this case of possible correlation between Covid 19 and TEN in pediatrics.
  • ||||||||||  prednisolone / Generic mfg., leflunomide / Generic mfg.
    Clinical, Journal:  IgA nephropathy associated with thalassemia: a case report. (Pubmed Central) -  Sep 11, 2021   
    Such lesions may be underdiagnosed, and this report emphasises the role of a thorough clinical inspection in PNOE cases. The possibility of occurrence of thalassemia should be considered in IgA nephropathy complicated with refractory anemia, especially in high-incidence areas of the disease.
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Acute Unilateral Vestibulopathy and Corticosteroid Treatment (clinicaltrials.gov) -  Sep 9, 2021   
    P4,  N=78, Terminated, 
    The possibility of occurrence of thalassemia should be considered in IgA nephropathy complicated with refractory anemia, especially in high-incidence areas of the disease. N=180 --> 78 | Trial completion date: Oct 2021 --> Mar 2021 | Recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Mar 2021; Placebo medication expired
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial completion date:  Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas (clinicaltrials.gov) -  Sep 8, 2021   
    P1/2,  N=18, Active, not recruiting, 
    N=180 --> 78 | Trial completion date: Oct 2021 --> Mar 2021 | Recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Mar 2021; Placebo medication expired Trial completion date: Aug 2021 --> Dec 2021
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Clinical, Journal:  Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases. (Pubmed Central) -  Sep 8, 2021   
    We conclude that such glomerulonephritis can occur during tocilizumab treatment, but this is rare. Clinicians should be aware of the possibility of paradoxical development of autoimmune diseases during tocilizumab therapy.
  • ||||||||||  Not your usual rash, DRESS syndrome () -  Sep 7, 2021 - Abstract #EUSEM2021EUSEM_586;    
    The patient stopped taking the allopurinol after rash appearance and started taking Loratadine asper advise of her GP with no help...She has background of AF on warfarin, IHD, HTN and gout...started on oral prednisolone and admitted for about 2 weeks...The overall mortality in DRESS syndrome is about 10%.1 The most common differential diagnoses for DRESS syndrome are Stevens-Johnson syndrome/toxic epidermal necrolysis, hyper-eosinphillic syndrome and Kawasaki disease. Important learning points is to recognised the typical rash with associated sepsis-like syndrome and manage DRESS with immediately stopping the offending drug and use of steroids.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron, Nucala (mepolizumab) / GSK
    Journal:  Successful Treatment of Mepolizumab- and Prednisolone-resistant Allergic Bronchopulmonary Aspergillosis with Dupilumab. (Pubmed Central) -  Sep 5, 2021   
    Alternative subcutaneous injection therapy with dupilumab (induction dose of 600 mg followed by a maintenance dose of 300 mg/2 weeks) enabled the successful withdrawal of oral PSL without clinical deterioration. This case demonstrates the potential utility of dupilumab for steroid-dependent ABPA via the synergistic suppression of IL-4 and IL-13 compared to monotherapy with anti-IL-5 antibody.
  • ||||||||||  prednisolone / Generic mfg.
    Clinical, Journal:  JAK2 mutation-positive polycythaemia vera associated with IgA vasculitis and nephrotic syndrome: a case report. (Pubmed Central) -  Aug 28, 2021   
    IgA vasculitis was diagnosed, and oral prednisolone therapy (30 mg/day) was initiated...Renal biopsy demonstrated mild mesangial proliferation with IgA deposits, but immunosuppressive therapy was partially effective. This case suggests that PV can be a complication of IgA vasculitis and that preventive measures for thrombosis should be taken in such cases.
  • ||||||||||  prednisolone / Generic mfg.
    [VIRTUAL] Nephrotic Syndrome and Type 1 Diabetes: a Therapeutic Approach () -  Aug 27, 2021 - Abstract #ESPE2021ESPE_740;    
    The aim of this case is not only to report a new case of nephrotic syndrome and type 1 diabetes mellitus, but also to make known a different approach concerning patients with diabetes mellitus insulin-treated and nephrotic syndrome. We report a better glycaemia control with insulin pump compared to multiple insulin injections in our patient, besides stating our approach during corticosteroid progressive weaning when in multiple insulin injection therapy.
  • ||||||||||  prednisolone / Generic mfg., azathioprine / Generic mfg.
    Clinical, Retrospective data, Journal:  Visual outcome of aquaporin-4 antibody-positive optic neuritis with maintenance therapy. (Pubmed Central) -  Aug 27, 2021   
    This study demonstrates that patients with AQP4Ab-positive optic neuritis without maintenance therapy had the poorest visual acuity and the most recurrences one year after first onset. These results indicate that reducing the number of recurrences with maintenance therapy could improve the visual outcomes in patients with AQP4Ab-positive optic neuritis.
  • ||||||||||  vigabatrin / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy:  Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm (clinicaltrials.gov) -  Aug 25, 2021   
    P=N/A,  N=250, Recruiting, 
    We aim to determine which is the likely cause of pulmonary embolism in patients with nephrotic syndrome. Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Jun 2023 --> Jun 2026
  • ||||||||||  prednisolone / Generic mfg., prednisone / Generic mfg.
    Journal:  Glycemic Control and Risk of Cellulitis. (Pubmed Central) -  Aug 22, 2021   
    Poor glycemic control was associated in this study with the development of cellulitis. The study also suggests that exposure to oral prednisolone increases the risk of cellulitis, pneumonia, and upper respiratory infection.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Enrollment closed, Trial primary completion date:  Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas (clinicaltrials.gov) -  Aug 19, 2021   
    P1/2,  N=18, Active, not recruiting, 
    Prompt diagnosis with FA and treatment with systemic or local steroids should be considered. Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2021 --> Nov 2020
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Clinical, Journal:  Anterior Scleritis Manifesting After Coronavirus Disease 2019: A Report of Two Cases. (Pubmed Central) -  Aug 14, 2021   
    These cases suggest that COVID-19 can be associated with anterior scleritis, which responds to immunosuppressive and biologic agents. Ophthalmologists should consider anterior scleritis in patients with COVID-19 who present with ocular pain and redness during the convalescent phase of the illness.
  • ||||||||||  cyclosporine / Generic mfg.
    Journal:  Mycoplasma-Induced Rash and Mucositis or Steven-Johnson Syndrome. (Pubmed Central) -  Aug 11, 2021   
    The girl recovered following therapy with azithromycin and oral prednisolone. The index case is instructive in highlighting a rare complication of a common infection, and delineates the importance of clinical suspicion and a systematic approach to evaluation and management of MIRM in patients with unusual mucosal lesions and skin rash.